In situ single-cell profiling sheds light on IFI27 localisation during SARS-CoV-2 infection.


Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 11 10 2023
revised: 02 02 2024
accepted: 03 02 2024
medline: 18 3 2024
pubmed: 21 2 2024
entrez: 20 2 2024
Statut: ppublish

Résumé

The utilization of single-cell resolved spatial transcriptomics to delineate immune responses during SARS-CoV-2 infection was able to identify M1 macrophages to have elevated expression of IFI27 in areas of infection.

Identifiants

pubmed: 38377798
pii: S2352-3964(24)00051-3
doi: 10.1016/j.ebiom.2024.105016
pmc: PMC10884333
pii:
doi:

Substances chimiques

IFI27 protein, human 0
Membrane Proteins 0

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

105016

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests EEK, LP, YK, YL, AN and ML are employees of Nanostring Technologies. KRS is a consultant for Sanofi, Roche and NovoNordisk. The opinions and data presented in this manuscript are of the authors and are independent of these relationships. Other co-authors have no conflict of interest to declare.

Auteurs

Chin Wee Tan (CW)

Division of Bioinformatics, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, 3052, Australia; Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3010, Australia; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.

Jinjin Chen (J)

Division of Bioinformatics, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, 3052, Australia; Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3010, Australia.

Ning Liu (N)

Division of Bioinformatics, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, 3052, Australia; Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3010, Australia; South Australian ImmunoGENomics Cancer Institute, The University of Adelaide, SA, Australia.

Dharmesh D Bhuva (DD)

Division of Bioinformatics, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, 3052, Australia; Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3010, Australia; South Australian ImmunoGENomics Cancer Institute, The University of Adelaide, SA, Australia.

Tony Blick (T)

Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.

James Monkman (J)

Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.

Caroline Cooper (C)

Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia; Princess Alexandra Hospital, Woolloongabba, QLD, Australia.

Malvika Kharbanda (M)

Division of Bioinformatics, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, 3052, Australia; Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3010, Australia; South Australian ImmunoGENomics Cancer Institute, The University of Adelaide, SA, Australia.

Kristen Feher (K)

Division of Bioinformatics, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, 3052, Australia; Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3010, Australia; South Australian ImmunoGENomics Cancer Institute, The University of Adelaide, SA, Australia.

Belinda Phipson (B)

Division of Bioinformatics, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, 3052, Australia; Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3010, Australia.

Emily E Killingbeck (EE)

Nanostring Technologies, Inc, Seattle, WA, USA.

Liuliu Pan (L)

Nanostring Technologies, Inc, Seattle, WA, USA.

Youngmi Kim (Y)

Nanostring Technologies, Inc, Seattle, WA, USA.

Yan Liang (Y)

Nanostring Technologies, Inc, Seattle, WA, USA.

Andy Nam (A)

Nanostring Technologies, Inc, Seattle, WA, USA.

Michael Leon (M)

Nanostring Technologies, Inc, Seattle, WA, USA.

Paulo Souza-Fonseca-Guimaraes (P)

Pontifícia Universidade Católica do Paraná, PUCPR, Curitiba, Paraná, Brazil.

Seigo Nagashima (S)

Laboratório de Patologia Experimental, PPGCS da PUCPR, Curitiba, Brazil.

Ana Paula Camargo Martins (AP)

Laboratório de Patologia Experimental, PPGCS da PUCPR, Curitiba, Brazil.

Cleber Machado-Souza (C)

Faculdades Pequeno Príncipe (FPP), Instituto de Pesquisa Pelé Pequeno Príncipe (IPPPP), R. Silva Jardim, 1632-ÁguaVerde, Curitiba, 80230-020, PR, Brazil.

Lucia de Noronha (L)

Laboratório de Patologia Experimental, PPGCS da PUCPR, Curitiba, Brazil.

Benjamin Tang (B)

Westmead Institute for Medical Research, Sydney, Australia.

Kirsty Short (K)

School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.

John Fraser (J)

Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia; Faculty of Medicine University of Queensland, Brisbane, QLD, Australia; St Andrew's War Memorial Hospital, UnitingCare, Spring Hill, QLD, Australia.

Gabrielle T Belz (GT)

Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.

Fernando Souza-Fonseca-Guimaraes (F)

Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.

Arutha Kulasinghe (A)

Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. Electronic address: arutha.kulasinghe@uq.edu.au.

Melissa J Davis (MJ)

Division of Bioinformatics, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, 3052, Australia; Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3010, Australia; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia; South Australian ImmunoGENomics Cancer Institute, The University of Adelaide, SA, Australia; Department of Clinical Pathology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3010, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH